Volumen: 18 # Number : 1
Publication Date : Enero - Abril Year: 2014
Recent advances in the pathophysiology
and treatment of the 5q- Syndrome
Authors: Chavarri Alicia, Massone Romina
Abstract: The 5q- syndrome it's a subtype of a myelodysplastic syndrome
(MDS) with a defined clinic, laboratory, citogenetic
alteration and treatment. Some genes are lost as result of the heterozygous deletion of the 5th chromosome. RPS14 is one of these genes, and its decreased expression results in an increase of p53 protein in the erythroid line, leathing to the characteristic anemia of this syndrome. MicroRNA's miR-145 and miR-146a are responsible of the alterations in the megakaryocytes and platelets. Lenalidomide
treatment induces clinical and cytogenetic remission, which results in high rates of transfusion independence
and improved quality of life.
Key words: 5q- syndrome, lenalidomide,
myelodysplastic syndrome
Pages : 31-39
|
